Loading...

Eli Lilly

NYSE:LLY
Snowflake Description

Established dividend payer with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LLY
NYSE
$107B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
LLY Share Price and Events
7 Day Returns
1.4%
NYSE:LLY
-1.2%
US Pharmaceuticals
-0.7%
US Market
1 Year Returns
41.8%
NYSE:LLY
8.5%
US Pharmaceuticals
3%
US Market
LLY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Eli Lilly (LLY) 1.4% 0.7% -5% 41.8% 56.6% 94%
US Pharmaceuticals -1.2% -1.3% -3.2% 8.5% 10.2% 16.5%
US Market -0.7% -2% 2.4% 3% 39.2% 42%
1 Year Return vs Industry and Market
  • LLY outperformed the Pharmaceuticals industry which returned 8.5% over the past year.
  • LLY outperformed the Market in United States of America which returned 3% over the past year.
Price Volatility
LLY
Industry
5yr Volatility vs Market
Related Companies

LLY Value

 Is Eli Lilly undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Eli Lilly to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Eli Lilly.

NYSE:LLY Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 12 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.6%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NYSE:LLY
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.643 (1 + (1- 21%) (15.57%))
0.814
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.81
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.814 * 5.96%)
7.58%

Discounted Cash Flow Calculation for NYSE:LLY using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Eli Lilly is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NYSE:LLY DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.58%)
2019 5,919.42 Analyst x3 5,502.35
2020 5,375.03 Analyst x5 4,644.29
2021 6,557.58 Analyst x4 5,266.85
2022 6,934.00 Analyst x1 5,176.79
2023 7,106.00 Analyst x1 4,931.41
2024 7,286.15 Est @ 2.54% 4,700.17
2025 7,475.13 Est @ 2.59% 4,482.32
2026 7,672.07 Est @ 2.63% 4,276.28
2027 7,876.39 Est @ 2.66% 4,080.84
2028 8,087.73 Est @ 2.68% 3,895.10
Present value of next 10 years cash flows $46,956.39
NYSE:LLY DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $8,087.73 × (1 + 2.73%) ÷ (7.58% – 2.73%)
$171,315.92
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $171,315.92 ÷ (1 + 7.58%)10
$82,506.70
NYSE:LLY Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $46,956.39 + $82,506.70
$129,463.09
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $129,463.09 / 920.83
$140.59
NYSE:LLY Discount to Share Price
Calculation Result
Value per share (USD) From above. $140.59
Current discount Discount to share price of $116.01
= -1 x ($116.01 - $140.59) / $140.59
17.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Eli Lilly is available for.
Intrinsic value
17%
Share price is $116.01 vs Future cash flow value of $140.59
Current Discount Checks
For Eli Lilly to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Eli Lilly's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Eli Lilly's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Eli Lilly's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Eli Lilly's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NYSE:LLY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $2.60
NYSE:LLY Share Price ** NYSE (2019-05-17) in USD $116.01
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 28 Publicly-Listed Pharmaceuticals Companies 22.57x
United States of America Market PE Ratio Median Figure of 3,088 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Eli Lilly.

NYSE:LLY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:LLY Share Price ÷ EPS (both in USD)

= 116.01 ÷ 2.60

44.65x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eli Lilly is overvalued based on earnings compared to the US Pharmaceuticals industry average.
  • Eli Lilly is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Eli Lilly's expected growth come at a high price?
Raw Data
NYSE:LLY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 44.65x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts
2.5%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.72x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

NYSE:LLY PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 44.65x ÷ 2.5%

17.81x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eli Lilly is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Eli Lilly's assets?
Raw Data
NYSE:LLY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $2.69
NYSE:LLY Share Price * NYSE (2019-05-17) in USD $116.01
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 180 Publicly-Listed Pharmaceuticals Companies 3.44x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
NYSE:LLY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:LLY Share Price ÷ Book Value per Share (both in USD)

= 116.01 ÷ 2.69

43.07x

* Primary Listing of Eli Lilly.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eli Lilly is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Eli Lilly's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Eli Lilly has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

LLY Future Performance

 How is Eli Lilly expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
2.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Eli Lilly expected to grow at an attractive rate?
  • Eli Lilly's earnings growth is positive but not above the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Eli Lilly's earnings growth is positive but not above the United States of America market average.
  • Eli Lilly's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NYSE:LLY Future Growth Rates Data Sources
Data Point Source Value (per year)
NYSE:LLY Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 2.5%
NYSE:LLY Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 12 Analysts 4.3%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 16.1%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NYSE:LLY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NYSE:LLY Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 26,746 8,544 6,354 8
2022-12-31 25,663 8,097 5,470 8
2021-12-31 24,948 7,584 6,061 10
2020-12-31 23,640 6,530 5,401 12
2019-12-31 22,196 7,120 8,029 12
NYSE:LLY Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 24,684 5,399 2,626
2018-12-31 24,556 5,525 3,232
2018-09-30 23,542 5,819 400
2018-06-30 23,138 5,579 -194
2018-03-31 22,607 5,712 1,074
2017-12-31 22,871 5,616 -204
2017-09-30 22,471 5,879 2,225
2017-06-30 22,005 5,659 2,447
2017-03-31 21,585 5,410 2,187
2016-12-31 21,222 4,851 2,738
2016-09-30 20,837 3,841 2,444
2016-06-30 20,605 3,284 2,466

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Eli Lilly's earnings are expected to grow by 2.5% yearly, however this is not considered high growth (20% yearly).
  • Eli Lilly's revenue is expected to grow by 4.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NYSE:LLY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from Eli Lilly Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:LLY Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 7.35 7.83 6.86 2.00
2020-12-31 6.10 6.59 5.61 4.00
2019-12-31 8.69 8.77 8.61 2.00
NYSE:LLY Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 2.60
2018-12-31 3.14
2018-09-30 0.39
2018-06-30 -0.19
2018-03-31 1.02
2017-12-31 -0.19
2017-09-30 2.11
2017-06-30 2.32
2017-03-31 2.07
2016-12-31 2.59
2016-09-30 2.31
2016-06-30 2.33

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Eli Lilly is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Eli Lilly's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Eli Lilly has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

LLY Past Performance

  How has Eli Lilly performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Eli Lilly's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Eli Lilly's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Eli Lilly's 1-year earnings growth exceeds its 5-year average (144.5% vs -16.3%)
  • Eli Lilly's earnings growth has exceeded the US Pharmaceuticals industry average in the past year (144.5% vs 41.9%).
Earnings and Revenue History
Eli Lilly's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Eli Lilly Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:LLY Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 24,684.10 2,625.90 6,568.20 5,430.10
2018-12-31 24,555.70 3,232.00 6,389.70 5,307.10
2018-09-30 23,541.60 399.90 6,181.90 5,270.80
2018-06-30 23,137.70 -194.00 6,142.90 5,267.50
2018-03-31 22,606.80 1,073.90 6,210.20 5,206.50
2017-12-31 22,871.30 -204.10 6,432.00 5,357.30
2017-09-30 22,471.10 2,224.60 6,475.40 5,321.00
2017-06-30 22,004.80 2,447.00 6,526.10 5,217.40
2017-03-31 21,585.30 2,186.70 6,482.60 5,281.20
2016-12-31 21,222.10 2,737.60 6,330.40 5,310.30
2016-09-30 20,837.20 2,444.20 6,460.30 5,237.50
2016-06-30 20,605.20 2,465.90 6,470.60 5,144.50
2016-03-31 20,179.10 2,319.00 6,483.40 4,978.10
2015-12-31 19,958.70 2,408.40 6,533.00 4,796.40
2015-09-30 19,704.40 2,358.50 6,534.50 4,537.90
2015-06-30 19,620.30 2,059.40 6,630.90 4,637.70
2015-03-31 19,577.20 2,192.10 6,659.40 4,663.60
2014-12-31 19,615.60 2,390.50 6,620.80 4,733.60
2014-09-30 20,303.10 2,689.50 6,774.50 5,023.30
2014-06-30 21,200.10 3,392.00 6,754.80 5,157.50
2014-03-31 22,194.20 3,864.70 6,958.50 5,292.50
2013-12-31 23,113.10 4,684.80 7,125.60 5,531.30
2013-09-30 23,261.70 4,784.60 7,149.50 5,519.00
2013-06-30 22,932.40 4,908.10 7,254.50 5,484.40
2013-03-31 22,603.40 4,625.50 7,318.00 5,474.70
2012-12-31 22,603.40 4,088.60 7,513.50 5,278.10
2012-09-30 22,692.60 4,119.50 7,669.40 5,170.30
2012-06-30 23,397.20 4,029.20 7,829.80 5,108.40

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Whilst Eli Lilly made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%), this is metric is skewed due to its high level of debt.
  • Eli Lilly used its assets less efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
  • Eli Lilly has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Eli Lilly's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Eli Lilly has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

LLY Health

 How is Eli Lilly's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Eli Lilly's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Eli Lilly is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Eli Lilly's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Eli Lilly's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Eli Lilly Company Filings, last reported 1 month ago.

NYSE:LLY Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 2,565.00 16,627.60 2,198.00
2018-12-31 10,909.10 12,847.20 8,155.60
2018-09-30 14,150.90 12,762.70 9,066.40
2018-06-30 11,620.80 12,289.80 6,930.70
2018-03-31 14,587.80 11,812.80 4,789.50
2017-12-31 11,667.90 13,717.20 8,034.90
2017-09-30 14,960.60 13,530.80 6,945.10
2017-06-30 14,169.70 12,341.00 5,437.30
2017-03-31 14,103.70 10,248.20 3,515.20
2016-12-31 14,080.50 10,305.70 6,041.00
2016-09-30 15,615.80 9,348.80 4,232.60
2016-06-30 14,656.20 9,331.30 3,944.70
2016-03-31 15,029.40 8,127.20 3,007.90
2015-12-31 14,590.30 7,978.90 4,451.80
2015-09-30 15,240.90 8,078.90 4,319.20
2015-06-30 14,705.40 8,001.20 4,230.90
2015-03-31 14,946.50 8,220.70 4,142.00
2014-12-31 15,388.10 8,171.70 4,827.00
2014-09-30 17,682.50 5,668.20 4,811.20
2014-06-30 17,994.80 5,326.20 5,126.50
2014-03-31 18,348.70 5,265.60 5,212.40
2013-12-31 17,640.70 5,213.80 5,417.40
2013-09-30 16,896.10 5,287.20 5,390.60
2013-06-30 15,236.40 5,314.00 4,723.40
2013-03-31 14,955.60 5,459.60 4,749.00
2012-12-31 14,773.90 5,531.30 5,684.30
2012-09-30 16,056.90 5,520.00 6,899.90
2012-06-30 14,307.90 5,509.30 5,261.50
  • Eli Lilly's level of debt (648.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (28.7% vs 648.2% today).
  • Debt is well covered by operating cash flow (32.5%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 41.6x coverage).
X
Financial health checks
We assess Eli Lilly's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Eli Lilly has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

LLY Dividends

 What is Eli Lilly's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.22%
Current annual income from Eli Lilly dividends. Estimated to be 2.34% next year.
If you bought $2,000 of Eli Lilly shares you are expected to receive $44 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Eli Lilly's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).
  • Eli Lilly's dividend is below the markets top 25% of dividend payers in United States of America (3.69%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NYSE:LLY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2000 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NYSE:LLY Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31 3.15 2.00
2022-12-31 3.08 2.00
2021-12-31 2.83 6.00
2020-12-31 2.68 9.00
2019-12-31 2.50 9.00
NYSE:LLY Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-05-06 2.580 2.229
2018-12-19 2.580 2.142
2018-10-15 2.250 2.014
2018-06-18 2.250 2.274
2018-05-07 2.250 2.699
2017-12-11 2.250 2.786
2017-10-16 2.080 2.464
2017-05-01 2.080 2.540
2016-12-12 2.080 2.621
2016-10-17 2.040 2.788
2016-06-20 2.040 2.565
2016-05-02 2.040 2.716
2015-12-08 2.040 2.649
2015-10-19 2.000 2.444
2015-06-15 2.000 2.381
2015-05-04 2.000 2.628
2014-12-15 2.000 2.804
2014-10-20 1.960 2.894
2014-06-16 1.960 3.104
2014-05-05 1.960 3.305
2013-12-16 1.960 3.510
2013-10-21 1.960 3.895
2013-06-18 1.960 3.807
2013-05-06 1.960 3.642
2012-12-17 1.960 3.626
2012-10-15 1.960 3.992
2012-06-19 1.960 4.381
2012-04-16 1.960 4.785
2011-12-12 1.960 4.915
2011-10-17 1.960 5.206
2011-06-20 1.960 5.292
2011-04-18 1.960 5.203
2010-12-13 1.960 5.612
2010-10-18 1.960 5.610
2010-06-21 1.960 5.530
2010-04-19 1.960 5.743
2009-12-14 1.960 5.509
2009-10-19 1.960 5.528
2009-06-22 1.960 5.836

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Eli Lilly's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.1x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (2.6x coverage).
X
Income/ dividend checks
We assess Eli Lilly's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Eli Lilly afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Eli Lilly has a total score of 5/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

LLY Management

 What is the CEO of Eli Lilly's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dave Ricks
COMPENSATION $17,230,337
AGE 50
TENURE AS CEO 2.3 years
CEO Bio

Mr. David A. Ricks, also known as Dave, served as a Director of Elanco Animal Health Incorporated until March 2019. He has been the Chief Executive Officer and President of Eli Lilly and Company since January 1, 2017 and has been its Chairman since June 1, 2017. Mr. Ricks served as the President of Lilly Bio-Medicines and Senior Vice President at Eli Lilly and Company from January 1, 2012 to January 1, 2017. He served as the President of Lilly USA, LLC since November 1, 2009 until 2012. He served as General Manager and President of Lilly China at Lilly USA, LLC from July 2008 to November 1, 2009. A 13-year Lilly veteran, he served in the U.S. affiliate for several years from 1998 to 2002 as a Marketing Manager and then as a District Sales Manager. He served as the President and General Manager of Eli Lilly Canada Inc. from April 2005 to July 2008, after roles as Director of Pharmaceutical Marketing and National Sales Director in Canada. He served as Vice President of Sales at Eli Lilly Canada, where he was responsible for sales results for key promoted retail products. Previously, he served as Vice President of Marketing at Eli Lilly Canada and was responsible for Lilly’s core brands, marketing operations and new product planning. He joined Eli Lilly and Company in 1996 as a business development associate and held several management roles in U.S. marketing and sales before moving to Lilly Canada. Prior to Lilly, he held various positions in the technology sector including positions with IBM Corporation in New York and Hewlett-Packard Corporation in Chelmsford, Massachusetts. He has been a Director of Eli Lilly and Company since January 7, 2017. . He has been a Director of Adobe Systems Incorporated since April 12, 2018 and also served as its Director since June 2017. He has deep expertise in product development, global sales and marketing, as well as public policy. He has significant global experience in the company's commercial operations. His Industry Memberships: Pharmaceutical Research and Manufacturers of America (PhRMA). His Non-profit Boards: Board of Governors for Riley Children’s Foundation and Central Indiana Community Partnership. Mr. Ricks obtained an MBA in Finance and Marketing from Indiana University in 1996 and a Bachelor of Science in Industrial Management from Purdue University in 1990.

CEO Compensation
  • Dave's compensation has been consistent with company performance over the past year.
  • Dave's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Eli Lilly management team in years:

2.8
Average Tenure
51
Average Age
  • The tenure for the Eli Lilly management team is about average.
Management Team

Dave Ricks

TITLE
Chairman
COMPENSATION
$17M
AGE
50
TENURE
2.3 yrs

Josh Smiley

TITLE
Senior VP & CFO
COMPENSATION
$5M
AGE
48
TENURE
1.3 yrs

Dan Skovronsky

TITLE
Senior VP & Chief Scientific Officer
COMPENSATION
$5M
AGE
44
TENURE
0.9 yrs

Mike Harrington

TITLE
Senior VP & General Counsel
COMPENSATION
$5M
AGE
55
TENURE
6.3 yrs

Jeff Simmons

TITLE
Senior VP & President of Elanco Animal Health
COMPENSATION
$5M
AGE
51
TENURE
11.3 yrs

Enrique Conterno

TITLE
Senior VP & President of Lilly Diabetes and Lilly USA
COMPENSATION
$5M
AGE
51
TENURE
9.5 yrs

Don Zakrowski

TITLE
Chief Accounting Officer & VP of Finance
TENURE
6.5 yrs

Martin Bott

TITLE
Vice President of Finance & Special Projects
AGE
56
TENURE
2.3 yrs

Aarti Shah

TITLE
Senior VP of Information Technology & Chief Information and Digital Officer
AGE
53
TENURE
2.8 yrs

Kristina Wright

TITLE
Director of Investor Relations
Board of Directors Tenure

Average tenure and age of the Eli Lilly board of directors in years:

8.8
Average Tenure
61.5
Average Age
  • The tenure for the Eli Lilly board of directors is about average.
Board of Directors

Dave Ricks

TITLE
Chairman
COMPENSATION
$17M
AGE
50
TENURE
1.9 yrs

Sidney Taurel

TITLE
Chairman Emeritus
COMPENSATION
$13M
AGE
69
TENURE
10.3 yrs

Ellen Marram

TITLE
Lead Independent Director
COMPENSATION
$338K
AGE
71
TENURE
7.1 yrs

J. Fyrwald

TITLE
Director
COMPENSATION
$298K
AGE
59
TENURE
13.5 yrs

Mike Eskew

TITLE
Director
COMPENSATION
$315K
AGE
68
TENURE
11.3 yrs

Raul Alvarez

TITLE
Director
COMPENSATION
$306K
AGE
63
TENURE
10.1 yrs

Kate Baicker

TITLE
Director
COMPENSATION
$302K
AGE
46
TENURE
7.4 yrs

William Kaelin

TITLE
Director
COMPENSATION
$309K
AGE
60
TENURE
6.9 yrs

Juan Luciano

TITLE
Director
COMPENSATION
$299K
AGE
57
TENURE
3.3 yrs

Kathi Seifert

TITLE
Director
COMPENSATION
$294K
AGE
68
TENURE
24.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
27. Mar 19 Sell Lilly Endowment, Inc, Endowment Arm Company 26. Mar 19 26. Mar 19 -205,000 $132.02 $-26,938,688
04. Mar 19 Sell Lilly Endowment, Inc, Endowment Arm Company 01. Mar 19 01. Mar 19 -210,000 $128.97 $-26,971,215
01. Mar 19 Sell Lilly Endowment, Inc, Endowment Arm Company 28. Feb 19 28. Feb 19 -200,000 $127.45 $-25,345,017
25. Feb 19 Sell Lilly Endowment, Inc, Endowment Arm Company 22. Feb 19 22. Feb 19 -195,000 $124.19 $-24,217,635
20. Feb 19 Sell Lilly Endowment, Inc, Endowment Arm Company 19. Feb 19 19. Feb 19 -205,000 $123.14 $-25,108,513
18. Jan 19 Sell Lilly Endowment, Inc, Endowment Arm Company 17. Jan 19 17. Jan 19 -136,577 $118.84 $-16,161,281
17. Jan 19 Sell Lilly Endowment, Inc, Endowment Arm Company 16. Jan 19 16. Jan 19 -1,657 $117.87 $-195,315
16. Jan 19 Sell Lilly Endowment, Inc, Endowment Arm Company 15. Jan 19 15. Jan 19 -51,766 $117.74 $-6,095,136
06. Dec 18 Sell Lilly Endowment, Inc, Endowment Arm Company 04. Dec 18 04. Dec 18 -15,500 $119.00 $-1,844,536
30. Nov 18 Sell Lilly Endowment, Inc, Endowment Arm Company 29. Nov 18 29. Nov 18 -185,000 $117.89 $-21,722,429
29. Nov 18 Sell Lilly Endowment, Inc, Endowment Arm Company 28. Nov 18 28. Nov 18 -190,000 $115.57 $-21,957,939
20. Nov 18 Sell Lilly Endowment, Inc, Endowment Arm Company 19. Nov 18 19. Nov 18 -195,000 $115.65 $-22,485,572
19. Nov 18 Sell Lilly Endowment, Inc, Endowment Arm Company 16. Nov 18 16. Nov 18 -200,000 $113.74 $-22,747,000
14. Nov 18 Sell Lilly Endowment, Inc, Endowment Arm Company 13. Nov 18 13. Nov 18 -2,460 $113.41 $-278,979
13. Nov 18 Sell Lilly Endowment, Inc, Endowment Arm Company 12. Nov 18 12. Nov 18 -202,540 $114.40 $-22,984,877
18. Oct 18 Sell Lilly Endowment, Inc, Endowment Arm Company 17. Oct 18 17. Oct 18 -174,696 $113.25 $-19,783,623
10. Oct 18 Sell Lilly Endowment, Inc, Endowment Arm Company 09. Oct 18 09. Oct 18 -10,672 $115.91 $-1,237,013
09. Oct 18 Sell Lilly Endowment, Inc, Endowment Arm Company 08. Oct 18 08. Oct 18 -14,632 $115.91 $-1,696,039
05. Oct 18 Sell Lilly Endowment, Inc, Endowment Arm Company 04. Oct 18 04. Oct 18 -116,038 $115.51 $-13,073,950
04. Oct 18 Sell Lilly Endowment, Inc, Endowment Arm Company 03. Oct 18 03. Oct 18 -78,962 $109.01 $-8,607,253
01. Oct 18 Sell Lilly Endowment, Inc, Endowment Arm Company 28. Sep 18 28. Sep 18 -107,553 $107.31 $-11,541,082
28. Sep 18 Sell Lilly Endowment, Inc, Endowment Arm Company 27. Sep 18 27. Sep 18 -92,447 $107.00 $-9,891,644
27. Sep 18 Sell Lilly Endowment, Inc, Endowment Arm Company 26. Sep 18 26. Sep 18 -134,410 $107.32 $-14,332,373
26. Sep 18 Sell Lilly Endowment, Inc, Endowment Arm Company 25. Sep 18 25. Sep 18 -55,590 $106.41 $-5,915,165
10. Sep 18 Sell Lilly Endowment, Inc, Endowment Arm Company 07. Sep 18 07. Sep 18 -180,000 $107.08 $-19,217,055
31. Aug 18 Sell Lilly Endowment, Inc, Endowment Arm Company 30. Aug 18 30. Aug 18 -190,000 $105.42 $-20,030,370
21. Aug 18 Sell Lilly Endowment, Inc, Endowment Arm Company 20. Aug 18 20. Aug 18 -195,000 $105.89 $-20,647,575
17. Aug 18 Sell Lilly Endowment, Inc, Endowment Arm Company 16. Aug 18 16. Aug 18 -200,000 $104.50 $-20,899,800
16. Aug 18 Sell Lilly Endowment, Inc, Endowment Arm Company 15. Aug 18 15. Aug 18 -151,793 $103.23 $-15,669,440
13. Aug 18 Sell Lilly Endowment, Inc, Endowment Arm Company 10. Aug 18 10. Aug 18 -3,587 $103.06 $-369,676
08. Aug 18 Sell Lilly Endowment, Inc, Endowment Arm Company 07. Aug 18 07. Aug 18 -24,620 $103.22 $-2,541,326
07. Aug 18 Sell Lilly Endowment, Inc, Endowment Arm Company 06. Aug 18 06. Aug 18 -195,000 $102.15 $-19,918,860
03. Aug 18 Sell Lilly Endowment, Inc, Endowment Arm Company 02. Aug 18 02. Aug 18 -190,000 $100.18 $-18,919,939
01. Aug 18 Sell Lilly Endowment, Inc, Endowment Arm Company 31. Jul 18 31. Jul 18 -205,000 $99.14 $-20,240,873
01. Feb 19 Buy Jackson Tai Individual 26. Jul 18 26. Jul 18 3,736 $95.22 $355,742
26. Jul 18 Sell Lilly Endowment, Inc, Endowment Arm Company 25. Jul 18 25. Jul 18 -190,000 $96.45 $-17,999,259
25. Jul 18 Sell Lilly Endowment, Inc, Endowment Arm Company 24. Jul 18 24. Jul 18 -185,000 $93.43 $-17,025,985
09. Jul 18 Sell Lilly Endowment, Inc, Endowment Arm Company 06. Jul 18 06. Jul 18 -180,000 $87.44 $-15,738,300
06. Jul 18 Sell Lilly Endowment, Inc, Endowment Arm Company 05. Jul 18 05. Jul 18 -170,000 $86.62 $-14,725,740
18. Jun 18 Sell Lilly Endowment, Inc, Endowment Arm Company 15. Jun 18 15. Jun 18 -180,000 $86.65 $-15,597,720
15. Jun 18 Sell Lilly Endowment, Inc, Endowment Arm Company 14. Jun 18 14. Jun 18 -107,698 $86.31 $-9,295,414
14. Jun 18 Buy Daniel Skovronsky Individual 14. Jun 18 14. Jun 18 10,000 $86.22 $862,200
14. Jun 18 Sell Lilly Endowment, Inc, Endowment Arm Company 13. Jun 18 13. Jun 18 -11,104 $86.27 $-957,953
12. Jun 18 Sell Lilly Endowment, Inc, Endowment Arm Company 11. Jun 18 11. Jun 18 -51,198 $86.38 $-4,422,637
05. Jun 18 Sell Lilly Endowment, Inc, Endowment Arm Company 04. Jun 18 04. Jun 18 -135,478 $85.13 $-11,532,565
04. Jun 18 Sell Lilly Endowment, Inc, Endowment Arm Company 01. Jun 18 01. Jun 18 -39,522 $85.31 $-3,371,661
31. May 18 Sell Lilly Endowment, Inc, Endowment Arm Company 30. May 18 30. May 18 -180,000 $83.85 $-15,092,640
X
Management checks
We assess Eli Lilly's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Eli Lilly has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

LLY News

Simply Wall St News

Have Insiders Been Buying Eli Lilly and Company (NYSE:LLY) Shares?

See our latest analysis for Eli Lilly Eli Lilly Insider Transactions Over The Last Year In the last twelve months, the biggest single purchase by an insider was when Senior VP &amp; Chief Scientific Officer Daniel Skovronsky bought US$862k worth of shares at a price of US$86.22 per share. … Insider Ownership I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. … With high insider ownership and encouraging transactions, it seems like Eli Lilly insiders think the business has merit.

Simply Wall St -

Eli Lilly and Company (NYSE:LLY) Delivered A Better ROE Than Its Industry

To keep the lesson grounded in practicality, we'll use ROE to better understand Eli Lilly and Company (NYSE:LLY). … Another way to think of that is that for every $1 worth of equity in the company, it was able to earn $0.30. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Eli Lilly and Company (NYSE:LLY): What Are The Future Prospects?

Since Eli Lilly and Company (NYSE:LLY) released its earnings in December 2018,. … the consensus outlook from analysts appear fairly confident, … the past 5-year average growth rate of -22%

Simply Wall St -

Does Eli Lilly and Company's (NYSE:LLY) Debt Level Pose A Problem?

Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Eli Lilly and Company (NYSE:LLY) a safer option. … the health of the financials determines whether the company continues to succeed. … Today we will look at Eli Lilly’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth.

Simply Wall St -

How Many Eli Lilly and Company (NYSE:LLY) Shares Do Institutions Own?

If you want to know who really controls Eli Lilly and Company (NYSE:LLY), then you'll have to look at the makeup of its share registry. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … institutions are noticeable on the share registry.

Simply Wall St -

What Should You Know About The Future Of Eli Lilly and Company's (NYSE:LLY)?

Help shape the future of investing tools and receive a $20 prize! … Eli Lilly and Company's (NYSE:LLY) most recent earnings announcement in December 2018 … negative earnings

Simply Wall St -

4 Days Left Before Eli Lilly and Company (NYSE:LLY) Will Be Trading Ex-Dividend

Important news for shareholders and potential investors in Eli Lilly and Company (NYSE:LLY): The dividend payment of US$0.65 per share will be distributed to shareholders on 08 March 2019, and the stock will begin trading ex-dividend at an earlier date, 14 February 2019. … Investors looking for higher income-generating stocks to add to their portfolio should keep reading, as I take a deeper dive into Eli Lilly's latest financial data to analyse its dividend attributes. … When assessing a stock as a potential addition to my dividend Portfolio, I look at these five areas:?

Simply Wall St -

Calculating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)

by taking the expected future cash flows and discounting them to their present value. … Discounted Cash Flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model

Simply Wall St -

Can Eli Lilly and Company (NYSE:LLY) Improve Its Returns?

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … That means that for every $1 worth of shareholders' equity, it generated $0.032 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

What Kind Of Shareholder Owns Most Eli Lilly and Company (NYSE:LLY) Stock?

The big shareholder groups in Eli Lilly and Company (NYSE:LLY) have power over the company. … We'd expect to see both institutions and retail investors owning a portion of the company. … institutions own shares in the company.

Simply Wall St -

LLY Company Info

Description

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as migraine prevention. In addition, it offers immunology products for the treatment of rheumatoid arthritis and plaque psoriasis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia, and acute coronary syndrome. Further, the company provides animal health products, such as cattle feed additives; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and enteric diseases in swine and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; Nektar Therapeutics; NextCure, Inc.; Dicerna Pharmaceuticals; AC Immune SA; and Avidity Biosciences, Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Details
Name: Eli Lilly and Company
LLY
Exchange: NYSE
Founded: 1876
$106,825,588,996
920,830,868
Website: http://www.lilly.com
Address: Eli Lilly and Company
Lilly Corporate Center,
Indianapolis,
Indiana, 46285,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE LLY Common Stock New York Stock Exchange US USD 02. Jan 1969
DB LLY Common Stock Deutsche Boerse AG DE EUR 02. Jan 1969
XTRA LLY Common Stock XETRA Trading Platform DE EUR 02. Jan 1969
LSE 0Q1G Common Stock London Stock Exchange GB CHF 02. Jan 1969
SWX LLY Common Stock SIX Swiss Exchange CH CHF 02. Jan 1969
ENXTPA LLY Common Stock Euronext Paris FR EUR 02. Jan 1969
BMV LLY * Common Stock Bolsa Mexicana de Valores MX MXN 02. Jan 1969
BATS-CHIXE LLYZ Common Stock BATS 'Chi-X Europe' GB CHF 02. Jan 1969
BOVESPA LILY34 BDR EACH REPR 0.5 COM NPV Bolsa de Valores de Sao Paulo BR BRL 24. Aug 2012
Number of employees
Current staff
Staff numbers
38,680
Eli Lilly employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 01:35
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/17
Last earnings filing: 2019/05/02
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.